liver-targeted hyperoxaluria therapy (Intellia Therapeutics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameliver-targeted hyperoxaluria therapy (Intellia Therapeutics)
Drug Alias Nameliver-targeted CRISPR/Cas9 gene editing therapy (Intellia Therapeutics)
ClassificationBiologics > Protein drugs > Recombinant proteinSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionHydroxyacid oxidase 1 inhibitorsL-lactate dehydrogenase A chain degraders
TargetsHydroxyacid oxidase 1L-lactate dehydrogenase A chain
Therapy Area/IndicationsHyperoxaluria
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesIntellia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIntellia Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsHyperoxaluria

Other Information

ATC CodeN/A
Related LinksN/A